Bloomage BioTechnology Corporation Limited (688363.SS)
- Previous Close
58.18 - Open
58.10 - Bid 58.77 x --
- Ask 58.82 x --
- Day's Range
57.85 - 59.18 - 52 Week Range
50.22 - 100.00 - Volume
1,269,070 - Avg. Volume
2,030,574 - Market Cap (intraday)
28.308B - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
35.19 - EPS (TTM)
1.67 - Earnings Date --
- Forward Dividend & Yield 0.61 (1.04%)
- Ex-Dividend Date Jun 21, 2023
- 1y Target Est
87.08
Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature name; and cosmetic grade sodium hyaluronate solutions for cosmetic products, including moisturizing, repairing, delay skin aging, and brightening under the Hybloom, miniHA, microHA, Hyacross, Hyacolor, and cationHA. The company also provides food-grade sodium hyaluronate for use in food/healthy food/dietary supplements under the HAPLEX name, as well as food-grade gamma aminobutyric acid under the Gabarelax name; hyaluronic acid for oral care under the Biomoist name; and animal care products under the HYAPET names. Bloomage BioTechnology Corporation Limited was founded in 2000 and is headquartered in Jinan, the People's Republic of China.
www.bloomagebioactive.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Related News
Performance Overview: 688363.SS
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688363.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688363.SS
Valuation Measures
Market Cap
28.31B
Enterprise Value
27.31B
Trailing P/E
35.19
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.54
Price/Book (mrq)
4.09
Enterprise Value/Revenue
4.36
Enterprise Value/EBITDA
29.04
Financial Highlights
Profitability and Income Statement
Profit Margin
9.66%
Return on Assets (ttm)
--
Return on Equity (ttm)
8.60%
Revenue (ttm)
6.08B
Net Income Avi to Common (ttm)
587.44M
Diluted EPS (ttm)
1.67
Balance Sheet and Cash Flow
Total Cash (mrq)
1.2B
Total Debt/Equity (mrq)
2.85%
Levered Free Cash Flow (ttm)
--
Research Analysis: 688363.SS
Company Insights: 688363.SS
688363.SS does not have Company Insights